Optimizing joint function: new knowledge and novel tools and treatments

Pfizer-sponsored satellite symposium at the European Haemophilia Consortium (EHC) congress. Understanding health outcomes: focus on haemophilia

At the 25th Annual European Haemophilia Consortium (EHC) Congress held in Prague, Czech Republic, in October 2012, Pfizer sponsored a satellite symposium entitled: 'Understanding Health Outcomes: Focus on Haemophilia'. Co-chaired by Brian O'Mahony (President of the EHC) and Brian Colvin (Director Medical and Scientific Affairs Haemophilia, Pfizer, Europe), the symposium examined the role of outcomes in haemophilia care in an age of evidence-based medicine. The current global economic recession has inevitably directed the spotlight of governments and health economists towards the cost of healthcare. Now is the time to focus on which outcome measures are important to collect in order to validate these costs, and how to standardise collection and reporting measures to support services and patient care. Using the United Kingdom (UK) as a case study, where initiatives in data collection and reporting are being trialled, Gerry Dolan opened the discussion by highlighting the importance of a multidisciplinary approach to ensuring success. Looking at specific measures of haemophilia healthcare, Carlo Martinoli focused on joint scores as a clinical outcome measure that can be systematically collected, and the role of ultrasound in bringing joint assessment into the hands of the haemophilia treater at the 'bedside'. Brian O'Mahony then brought the discussion full circle by highlighting the role of the patient in the multidisciplinary care team and the importance of the patient voice in the assessment and critical examination of health outcomes by payers and government bodies. The meeting closed by summarising the importance of collaboration between patients and their carers; physicians; members of the healthcare team; and budget holders in advancing haemophilia care, to provide the best possible care with optimum long-term outcomes for people with haemophilia.

Nuclear factor (NF)-κB and its associated pathways are major molecular regulators of blood-induced joint damage in a murine model of hemophilia

BACKGROUND

The present study was designed to investigate the molecular signaling events from onset of bleeding through the development of arthropathy in a murine model of hemophilia A.

METHODS AND RESULTS

A sharp-injury model of hemarthrosis was used. A global gene expression array on joint-specific RNA isolated 3 h post-injury revealed nuclear factor-kappa B (NF-κB) as the major transcription factor triggering inflammation. As a number of genes encoding the cytokines, growth factors and hypoxia regulating factors are known to be activated by NF-κB and many of these are part of the pathogenesis of various joint diseases, we reasoned that NF-κB-associated pathways may play a crucial role in blood-induced joint damage. To further understand its role, we screened NF-κB-associated pathways between 1 h to 90 days after injury. After a single articular bleed, distinct members of the NF-κB family (NF-κB1/NF-κB2/RelA/RelB) and their responsive pro-inflammatory cytokines (IL-1β/IL-6/IFNγ/TNFα) were significantly up-regulated (> 2 fold, P < 0.05) in injured vs. control joints at the various time-points analyzed (1 h/3 h/7 h/24 h). After multiple bleeds (days 30/60/75/90), there was increased expression of NF-κB-associated factors that contribute to hypoxia (HIF-1α, 3.3-6.5 fold), angiogenesis (VEGF-α, 2.5-4.4 fold) and chondrocyte damage (matrix metalloproteinase-13, 2.8-3.8 fold) in the injured joints. Micro RNAs (miR) that are known to regulate NF-κB activation (miRs-9 and 155), inflammation (miRs-16, 155 and 182) and apoptosis (miRs-19a, 155 and 186) were also differentially expressed (-4 to +13-fold) after joint bleeding, indicating that the small RNAs could modulate the arthropathy phenotype.

CONCLUSIONS

These data suggest that NF-κB-associated signaling pathways are involved in the development of hemophilic arthropathy.